Top

Published in:

01-03-2020 | Educational Review

Diagnostics, treatment, and immune response in BK polyomavirus infection after pediatric kidney transplantation

Authors: Thurid Ahlenstiel-Grunow, Lars Pape

Published in: Pediatric Nephrology | Issue 3/2020

Abstract

After pediatric kidney transplantation BK polyomavirus (BKPyV) infections are associated with an increased risk of graft loss by BKPyV-associated nephropathy (BkPyVAN). However, suitable prognostic markers for the individual outcome of BKPyV infections are missing and the management of therapeutic interventions remains a challenge to the success of pediatric kidney transplantation. This review gives an overview on current diagnostic and therapeutic strategies in the field of BKPyV infections after pediatric kidney transplantation. Methods determining the individual immune response to BKPyV are described and their usability is discussed. There is growing evidence that BKPyV-specific T cells (BKPyV-Tvis) may serve as prognostic markers in order to steer immunosuppressive therapy in pediatric kidney recipients with BKPyV viremia in future. Prospective randomized trials in viremic kidney recipients comparing Tvis-steered therapeutic intervention with standard reduction of immunosuppression are needed before implementation of BKPyV-Tvis monitoring in routine care of BKPyV infections.

Ramos E, Drachenberg CB, Wali R, Hirsch HH (2009) The decade of polyomavirus BK-associated nephropathy: state of affairs. Transplantation 87:621–630PubMedCrossRef

Hirsch HH, Knowles W, Dickenmann M, Passweg J, Klimkait T, Mihatsch MJ, Steiger J (2002) Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med 347:488–496PubMedCrossRef

Elfadawy N, Flechner SM, Schold JD, Srinivas TR, Poggio E, Fatica R, Avery R, Mossad SB (2014) Transient versus persistent BK viremia and long-term outcomes after kidney and kidney-pancreas transplantation. Clin J Am Soc Nephrol 9:553–561PubMedPubMedCentralCrossRef

Knowles WA, Pipkin P, Andrews N, Vyse A, Minor P, Brown DW, Miller E (2003) Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol 71:115–123PubMedCrossRef

Egli A, Infanti L, Dumoulin A, Buser A, Samaridis J, Stebler C, Gosert R, Hirsch HH (2009) Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis 199:837–846CrossRefPubMed

Chesters PM, Heritage J, McCance DJ (1983) Persistence of DNA sequences of BK virus and JC virus in normal human tissues and in diseased tissues. J Infect Dis 147:676–684PubMedCrossRef

Masutani K (2014) Current problems in screening, diagnosis and treatment of polyomavirus BK nephropathy. Nephrology 19(Suppl 3):11–16PubMedCrossRef

Vasudev B, Hariharan S, Hussain SA, Zhu YR, Bresnahan BA, Cohen EP (2005) BK virus nephritis: risk factors, timing, and outcome in renal transplant recipients. Kidney Int 68:1834–1839PubMedCrossRef

Comoli P, Binggeli S, Ginevri F, Hirsch HH (2006) Polyomavirus-associated nephropathy: update on BK virus-specific immunity. Transpl Infect Dis 8:86–94PubMedCrossRef

10.

Hirsch HH, Vincenti F, Friman S, Tuncer M, Citterio F, Wiecek A, Scheuermann EH, Klinger M, Russ G, Pescovitz MD, Prestele H (2013) Polyomavirus BK replication in de novo kidney transplant patients receiving tacrolimus or cyclosporine: a prospective, randomized, multicenter study. Am J Transplant 13:136–145PubMedCrossRef

11.

Dharnidharka VR, Cherikh WS, Abbott KC (2009) An OPTN analysis of national registry data on treatment of BK virus allograft nephropathy in the United States. Transplantation 87:1019–1026PubMedCrossRef

12.

Schold JD, Rehman S, Kayle LK, Magliocca J, Srinivas TR, Meier-Kriesche HU (2009) Treatment for BK virus: incidence, risk factors and outcomes for kidney transplant recipients in the United States. Transpl Int 22:626–634PubMedCrossRef

13.

Hocker B, Schneble L, Murer L, Carraro A, Pape L, Kranz B, Oh J, Zirngibl M, Dello Strologo L, Buscher A, Weber LT, Awan A, Pohl M, Bald M, Printza N, Rusai K, Peruzzi L, Topaloglu R, Fichtner A, Krupka K, Koster L, Bruckner T, Schnitzler P, Hirsch HH, Tonshoff B (2018) Epidemiology of and risk factors for BK polyomavirus replication and nephropathy in pediatric renal transplant recipients: an international CERTAIN registry study. Transplantation. https://doi.org/10.1097/TP.0000000000002414

14.

Brennan DC, Agha I, Bohl DL, Schnitzler MA, Hardinger KL, Lockwood M, Torrence S, Schuessler R, Roby T, Gaudreault-Keener M, Storch GA (2005) Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant 5:582–594PubMedCrossRef

15.

Pascual J, Royuela A, Fernandez AM, Herrero I, Delgado JF, Sole A, Guirado L, Serrano T, de la Torre-Cisneros J, Moreno A, Cordero E, Gallego R, Lumbreras C, Aguado JM, Spanish Society of Transplantation Virological and Immune Response Investigation Study Group (2016) Role of mTOR inhibitors for the control of viral infection in solid organ transplant recipients. Transpl Infect Dis 18:819–831PubMedCrossRef

16.

Tedesco Silva H, Cibrik D, Johnston T, Lackova E, Mange K, Panis C, Walker R, Wang Z, Zibari G, Kim YS (2010) Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. Am J Transplant 10:1401–1413PubMedCrossRef

17.

Moscarelli L, Caroti L, Antognoli G, Zanazzi M, Di Maria L, Carta P, Minetti E (2013) Everolimus leads to a lower risk of BKV viremia than mycophenolic acid in de novo renal transplantation patients: a single-center experience. Clin Transpl 27:546–554CrossRef

18.

Suwelack B, Malyar V, Koch M, Sester M, Sommerer C (2012) The influence of immunosuppressive agents on BK virus risk following kidney transplantation, and implications for choice of regimen. Transplant Rev 26:201–211CrossRef

19.

Pape L, Tonshoff B, Hirsch HH, Members of the Working Group 'Transplantation' of the European Society for Paediatric Nephrology (2016) Perception, diagnosis and management of BK polyomavirus replication and disease in paediatric kidney transplant recipients in europe. Nephrol Dial Transplant 31:842–847PubMedCrossRef

20.

Viscount HB, Eid AJ, Espy MJ, Griffin MD, Thomsen KM, Harmsen WS, Razonable RR, Smith TF (2007) Polyomavirus polymerase chain reaction as a surrogate marker of polyomavirus-associated nephropathy. Transplantation 84:340–345PubMedCrossRef

21.

Egli A, Dumoulin A, Köhli S, Hisch HH (2009) Polyomavirus BK after kidney transplantation - role of molecular and immunologic markers. Trend Transplant 3:85–102

22.

Ginevri F, Azzi A, Hirsch HH, Basso S, Fontana I, Cioni M, Bodaghi S, Salotti V, Rinieri A, Botti G, Perfumo F, Locatelli F, Comoli P (2007) Prospective monitoring of polyomavirus BK replication and impact of pre-emptive intervention in pediatric kidney recipients. Am J Transplant 7:2727–2735PubMedCrossRef

23.

Hirsch HH, Babel N, Comoli P, Friman V, Ginevri F, Jardine A, Lautenschlager I, Legendre C, Midtvedt K, Munoz P, Randhawa P, Rinaldo CH, Wieszek A (2014) European perspective on human polyomavirus infection, replication and disease in solid organ transplantation. Clin Microbiol Infect Suppl 7:74–88CrossRef

24.

Hirsch HH, Randhawa P, AST Infectious Diseases Community of Practice (2013) BK polyomavirus in solid organ transplantation. Am J Transplant 13(Suppl 4):179–188PubMedCrossRef

25.

Almeras C, Vetromile F, Garrigue V, Szwarc I, Foulongne V, Mourad G (2011) Monthly screening for BK viremia is an effective strategy to prevent BK virus nephropathy in renal transplant recipients. Transpl Infect Dis 13:101–108PubMedCrossRef

26.

Schachtner T, Babel N, Reinke P (2015) Different risk factor profiles distinguish early-onset from late-onset BKV-replication. Transpl Int 28:1081–1091PubMedCrossRef

27.

Sar A, Worawichawong S, Benediktsson H, Zhang J, Yilmaz S, rpkov K (2011) Interobserver agreement for polyomavirus nephropathy grading in renal allografts using the working proposal from the 10th banff conference on allograft pathology. Hum Pathol 42:2018–2024PubMedCrossRef

28.

Drachenberg CB, Papadimitriou JC, Hirsch HH, Wali R, Crowder C, Nogueira J, Cangro CB, Mendley S, Mian A, Ramos E (2004) Histological patterns of polyomavirus nephropathy: correlation with graft outcome and viral load. Am J Transplant 4:2082–2092PubMedCrossRef

29.

Wu SW, Chang HR, Lian JD (2009) The effect of low-dose cidofovir on the long-term outcome of polyomavirus-associated nephropathy in renal transplant recipients. Nephrol Dial Transplant 24:1034–1038PubMedCrossRef

30.

Kuypers DR, Bammens B, Claes K, Evenepoel P, Lerut E, Vanrenterghem Y (2009) A single-centre study of adjuvant cidofovir therapy for BK virus interstitial nephritis (BKVIN) in renal allograft recipients. J Antimicrob Chemother 63:417–419PubMedCrossRef

31.

Kuypers DR, Vandooren AK, Lerut E, Evenepoel P, Claes K, Snoeck R, Naesens L, Vanrenterghem Y (2005) Adjuvant low-dose cidofovir therapy for BK polyomavirus interstitial nephritis in renal transplant recipients. Am J Transplant 5:1997–2004PubMedCrossRef

32.

Bernhoff E, Gutteberg TJ, Sandvik K, Hirsch HH, Rinaldo CH (2008) Cidofovir inhibits polyomavirus BK replication in human renal tubular cells downstream of viral early gene expression. Am J Transplant 8:413–1422CrossRef

33.

Rinaldo CH, Hirsch HH (2007) Antivirals for the treatment of polyomavirus BK replication. Expert Rev Anti-Infect Ther 5:105–115PubMedCrossRef

34.

Josephson MA, Williams JW, Chandraker A, Randhawa PS (2006) Polyomavirus-associated nephropathy: update on antiviral strategies. Transpl Infect Dis 8:95–101PubMedCrossRef

35.

Jung YH, Moon KC, Ha JW, Kim SJ, Ha IS, Cheong HI, Kang HG (2013) Leflunomide therapy for BK virus allograft nephropathy after pediatric kidney transplantation. Pediatr Transplant 17:E50–E54PubMedCrossRef

36.

Zaman RA, Ettenger RB, Cheam H, Malekzadeh MH, Tsai EW (2014) A novel treatment regimen for BK viremia. Transplantation 97:1166–1171PubMedCrossRef

37.

Faguer S, Hirsch HH, Kamar N, Guilbeau-Frugier C, Ribes D, Guitard J, Esposito L, Cointault O, Modesto A, Lavit M, Mengelle C, Rostaing L (2007) Leflunomide treatment for polyomavirus BK-associated nephropathy after kidney transplantation. Transpl Int 20:962–969PubMedCrossRef

38.

Josephson MA, Gillen D, Javaid B, Kadambi P, Meehan S, Foster P, Harland R, Thistlethwaite RJ, Garfinkel M, Atwood W, Jordan J, Sadhu M, Millis MJ, Williams J (2006) Treatment of renal allograft polyoma BK virus infection with leflunomide. Transplantation 81:704–710PubMedCrossRef

39.

Gabardi S, Waikar SS, Martin S, Roberts K, Chen J, Borgi L, Sheashaa H, Dyer C, Malek SK, Tullius SG, Vadivel N, Grafals M, Abdi R, Najafian N, Milford E, Chandraker A (2010) Evaluation of fluoroquinolones for the prevention of BK viremia after renal transplantation. Clin J Am Soc Nephrol 5:1298–1304PubMedPubMedCentralCrossRef

40.

Sharma BN, Li R, Bernhoff E, Gutteberg TJ, Rinaldo CH (2011) Fluoroquinolones inhibit human polyomavirus BK (BKV) replication in primary human kidney cells. Antivir Res 92:115–123PubMedCrossRef

41.

Sener A, House AA, Jevnikar AM, Boudville N, McAlister VC, Muirhead N, Rehman F, Luke PP (2006) Intravenous immunoglobulin as a treatment for BK virus associated nephropathy: one-year follow-up of renal allograft recipients. Transplantation 81:117–120PubMedCrossRef

42.

Farasati NA, Shapiro R, Vats A, Randhawa P (2005) Effect of leflunomide and cidofovir on replication of BK virus in an in vitro culture system. Transplantation 79:116–118PubMedCrossRef

43.

Schaub S, Hirsch HH, Dickenmann M, Steiger J, Mihatsch MJ, Hopfer H, Mayr M (2010) Reducing immunosuppression preserves allograft function in presumptive and definitive polyomavirus-associated nephropathy. Am J Transplant 10:2615–2623PubMedCrossRef

44.

Almeras C, Foulongne V, Garrigue V, Szwarc I, Vetromile F, Segondy M, Mourad G (2008) Does reduction in immunosuppression in viremic patients prevent BK virus nephropathy in de novo renal transplant recipients? A prospective study. Transplantation 85:1099–1104PubMedCrossRef

45.

Acott P, Babel N (2012) BK virus replication following kidney transplant: does the choice of immunosuppressive regimen influence outcomes? Ann Transplant 17:86–99PubMed

46.

Hirsch HH, Yakhontova K, Lu M, Manzetti J (2016) BK polyomavirus replication in renal tubular epithelial cells is inhibited by sirolimus, but activated by tacrolimus through a pathway involving FKBP-12. Am J Transplant 16:821–832PubMedCrossRef

47.

Buehrig CK, Lager DJ, Stegall MD, Kreps MA, Kremers WK, Gloor JM, Schwab TR, Velosa JA, Fidler ME, Larson TS, Griffin MD (2003) Influence of surveillance renal allograft biopsy on diagnosis and prognosis of polyomavirus-associated nephropathy. Kidney Int 64:665–673PubMedCrossRef

48.

Drachenberg CB, Papadimitriou JC, Wali R, Nogueira J, Mendley S, Hirsch HH, Cangro CB, Klassen DK, Weir MR, Bartlett ST, Ramos E (2004) Improved outcome of polyoma virus allograft nephropathy with early biopsy. Transplant Proc 36:758–759PubMedCrossRef

49.

Ramos E, Drachenberg CB, Papadimitriou JC, Hamze O, Fink JC, Klassen DK, Drachenberg RC, Wiland A, Wali R, Cangro CB, Schweitzer E, Bartlett ST, Weir MR (2002) Clinical course of polyoma virus nephropathy in 67 renal transplant patients. J Am Soc Nephrol 13:2145–2151PubMedCrossRef

50.

Schachtner T, Muller K, Stein M, Diezemann C, Sefrin A, Babel N, Reinke P (2011) BK virus-specific immunity kinetics: a predictor of recovery from polyomavirus BK-associated nephropathy. Am J Transplant 11:2443–2452PubMedCrossRef

51.

Schachtner T, Stein M, Sefrin A, Babel N, Reinke P (2014) Inflammatory activation and recovering BKV-specific immunity correlate with self-limited BKV replication after renal transplantation. Transpl Int 27:290–301PubMedCrossRef

52.

Egli A, Dumoulin A, Kohli S, Hirsch HH (2006) Polyomavirus BK after kidney transplantation - role of meolecular and immunologic markers. Trend Transplant 3:85–102

53.

Leuenberger D, Andresen PA, Gosert R, Binggeli S, Strom EH, Bodaghi S, Rinaldo CH, Hirsch HH (2007) Human polyomavirus type 1 (BK virus) agnoprotein is abundantly expressed but immunologically ignored. Clin Vaccine Immunol 14:959–968PubMedPubMedCentralCrossRef

54.

Chen Y, Trofe J, Gordon J, Du Pasquier RA, Roy-Chaudhury P, Kuroda MJ, Woodle ES, Khalili K, Koralnik IJ (2006) Interplay of cellular and humoral immune responses against BK virus in kidney transplant recipients with polyomavirus nephropathy. J Virol 80:3495–3505PubMedPubMedCentralCrossRef

55.

Randhawa PS, Gupta G, Vats A, Shapiro R, Viscidi RP (2006) Immunoglobulin G, A, and M responses to BK virus in renal transplantation. Clin Vaccine Immunol 13:1057–1063PubMedPubMedCentralCrossRef

56.

Leboeuf C, Wilk S, Achermann R, Binet I, Golshayan D, Hadaya K, Hirzel C, Hoffmann M, Huynh-Do U, Koller MT, Manuel O, Mueller NJ, Mueller TF, Schaub S, van Delden C, Weissbach FH, Hirsch HH, Swiss Transplant Cohort Study (2017) BK polyomavirus-specific 9mer CD8 T cell responses correlate with clearance of BK viremia in kidney transplant recipients: first report from the swiss transplant cohort study. Am J Transplant 17:2591–2600PubMedCrossRef

57.

Sester M, Leboeuf C, Schmidt T, Hirsch HH (2016) The “ABC” of virus-specific T cell immunity in solid organ transplantation. Am J Transplant 16:1697–1706PubMedCrossRef

58.

Sester M, Sester U, Gartner B, Heine G, Girndt M, Mueller-Lantzsch N, Meyerhans A, Kohler H (2001) Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation. Transplantation 71:287–1294CrossRef

59.

Sester U, Presser D, Dirks J, Gartner BC, Kohler H, Sester M (2008) PD-1 expression and IL-2 loss of cytomegalovirus- specific T cells correlates with viremia and reversible functional anergy. Am J Transplant 8:1486–1497PubMedCrossRef

60.

Binggeli S, Egli A, Schaub S, Binet I, Mayr M, Steiger J, Hirsch HH (2007) Polyomavirus BK-specific cellular immune response to VP1 and large T-antigen in kidney transplant recipients. Am J Transplant 7:131–1139CrossRef

61.

Prosser SE, Orentas RJ, Jurgens L, Cohen EP, Hariharan S (2008) Recovery of BK virus large T-antigen-specific cellular immune response correlates with resolution of bk virus nephritis. Transplantation 85:185–192PubMedCrossRef

62.

Costa C, Mantovani S, Piceghello A, Di Nauta A, Sinesi F, Sidoti F, Messina M, Cavallo R (2014) Evaluation of polyomavirus BK cellular immune response by an ELISpot assay and relation to viral replication in kidney transplant recipients. New Microbiol 37:219–223PubMed

63.

Schachtner T, Stein M, Babel N, Reinke P (2015) The loss of BKV-specific immunity from pretransplantation to posttransplantation identifies kidney transplant recipients at increased risk of BKV replication. Am J Transplant 15:2159–2169PubMedCrossRef

Title: Diagnostics, treatment, and immune response in BK polyomavirus infection after pediatric kidney transplantation
Authors: Thurid Ahlenstiel-Grunow
Lars Pape
Publication date: 01-03-2020
Publisher: Springer Berlin Heidelberg
Published in: Pediatric Nephrology / Issue 3/2020
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI: https://doi.org/10.1007/s00467-018-4164-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Diagnostics, treatment, and immune response in BK polyomavirus infection after pediatric kidney transplantation

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2020

A cross-sectional study on uric acid levels among Chinese adolescents

Sex and age as determinants for high blood pressure in pediatric renal transplant recipients: a longitudinal analysis of the CERTAIN Registry

Growth plate alterations in chronic kidney disease

Immunoglobulin serum levels in rituximab-treated patients with steroid-dependent nephrotic syndrome

Energy and protein requirements for children with CKD stages 2-5 and on dialysis–clinical practice recommendations from the Pediatric Renal Nutrition Taskforce

A boy with IgA vasculitis and anuria: Questions